Fish & Richardson and client Gilead Sciences Inc. are slated to receive nearly $14 million in legal fees after exposing patent misconduct by Merck & Co. Inc. that helped Gilead shake off a $200 million infringement verdict.

U.S. District Judge Beth Labson Freeman in San Jose, California, on Friday awarded Gilead a little more than $12.5 million for Fish & Richardson's work on the patent infringement case through June 30, 2016. The judge allotted an additional $1.37 million to Deloitte Review Services for document review and production it did.

The ultimate fee amount is short of the $15.5 million Gilead requested in the case, which involved infringement allegations against Gilead related to patents for the Hepatitis C medications Sovaldi and Harvoni. After a jury issued Merck a $200 million infringement verdict last year, Freeman scrapped it based on an “unclean hands” defense pushed by Fish & Richardson on Gilead's behalf.